Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:SPHS
- CUSIP: N/A
- Web: www.sophiris.com
Capitalization:- Market Cap: $70.29 million
- Outstanding Shares: 30,111,000
Average Prices:- 50 Day Moving Avg: $2.03
- 200 Day Moving Avg: $2.32
- 52 Week Range: $1.80 - $3.48
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.09
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.44 per share
- Price / Book: 5.32
Profitability:- EBIDTA: ($11,200,000.00)
- Return on Equity: -83.08%
- Return on Assets: -39.68%
Debt:- Current Ratio: 15.08%
- Quick Ratio: 15.08%
Misc:- Average Volume: 187,975 shs.
- Beta: 1.52
- Short Ratio: 17.83
Frequently Asked Questions for Sophiris Bio (NASDAQ:SPHS)
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio, Inc. (NASDAQ:SPHS) posted its earnings results on Monday, May, 15th. The company reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.00. View Sophiris Bio's Earnings History.
When will Sophiris Bio make its next earnings announcement?
Where is Sophiris Bio's stock going? Where will Sophiris Bio's stock price be in 2017?
5 equities research analysts have issued twelve-month price objectives for Sophiris Bio's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Sophiris Bio's stock price to reach $6.60 in the next twelve months. View Analyst Ratings for Sophiris Bio.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include Peregrine Pharmaceuticals (PPHM), Regulus Therapeutics (RGLS), Marinus Pharmaceuticals (MRNS), CTI BioPharma Corp. (CTIC), Sorrento Therapeutics (SRNE), Neovasc (NVCN), MediWound (MDWD), GTx (GTXI), Novelion Therapeutics (NVLN), Oramed Pharmaceuticals (ORMP), SeaSpine Holdings Corporation (SPNE), Axsome Therapeutics (AXSM), Nuvectra Corporation (NVTR), Trinity Biotech PLC (TRIB), ProQR Therapeutics N.V. (PRQR), Agile Therapeutics (AGRX), Cidara Therapeutics (CDTX) and Cumberland Pharmaceuticals (CPIX).
Who owns Sophiris Bio stock?
Sophiris Bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.43%), Palo Alto Investors LLC (0.82%), Mesirow Financial Investment Management Inc. (0.18%) and JPMorgan Chase & Co. (0.08%). View Institutional Ownership Trends for Sophiris Bio.
Who sold Sophiris Bio stock? Who is selling Sophiris Bio stock?
Who bought Sophiris Bio stock? Who is buying Sophiris Bio stock?
How do I buy Sophiris Bio stock?
Shares of Sophiris Bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of Sophiris Bio stock can currently be purchased for approximately $2.34.
MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Sophiris Bio (NASDAQ:SPHS)Earnings History by Quarter for Sophiris Bio (NASDAQ SPHS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.10) | | | | | N/A |  |
| 5/15/2017 | Q1 2017 | ($0.09) | ($0.09) | | | View | N/A | |
| 3/27/2017 | Q4 2016 | ($0.11) | ($0.02) | | | View | N/A | |
| 5/16/2016 | Q1 | ($0.19) | ($0.13) | | | View | N/A | |
| 3/23/2016 | Q4 | | ($0.15) | | | View | N/A | |
| 11/16/2015 | Q3 | | ($0.22) | | | View | N/A | |
| 5/13/2015 | | ($0.30) | ($0.26) | | | View | N/A | |
| 3/10/2015 | | ($0.47) | ($0.31) | | | View | N/A | |
| 11/13/2014 | | ($0.54) | ($0.49) | | | View | N/A | |
| 5/13/2014 | Q114 | ($0.50) | ($0.52) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Sophiris Bio (NASDAQ:SPHS)2017 EPS Consensus Estimate: ($0.34)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.08) | ($0.08) | ($0.08) |
| Q2 2017 | 1 | ($0.08) | ($0.08) | ($0.08) |
| Q3 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q4 2017 | 1 | ($0.09) | ($0.09) | ($0.09) |
(Data provided by Zacks Investment Research)
Dividend History for Sophiris Bio (NASDAQ:SPHS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sophiris Bio (NASDAQ:SPHS)Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 6.01%
Insider Trades by Quarter for Sophiris Bio (NASDAQ:SPHS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/15/2014 | Boxer Capital, Llc | Major Shareholder | Sell | 881,479 | $0.61 | $537,702.19 | |
| 11/14/2014 | Randall E Woods | Insider | Buy | 3,000 | $2.43 | $7,290.00 | |
| 9/19/2014 | Gerald T Proehl | Director | Buy | 10,000 | $3.16 | $31,600.00 | |
| 7/10/2014 | Randall E Woods | Insider | Buy | 1,000 | $2.65 | $2,650.00 | |
| 7/9/2014 | Randall E Woods | Insider | Buy | 1,000 | $2.66 | $2,660.00 | |
| 6/6/2014 | James L Heppell | Director | Sell | 19,231 | $2.59 | $49,808.29 | |
| 8/22/2013 | Randall E Woods | CEO | Buy | 2,500 | $4.50 | $11,250.00 | |
| 8/20/2013 | Peter T Slover | CFO | Buy | 4,680 | $4.25 | $19,890.00 | |
| 8/19/2013 | Randall E Woods | CEO | Buy | 10,000 | $4.29 | $42,900.00 | |
| 8/16/2013 | Boxer Capital, Llc | Major Shareholder | Buy | 1,600,000 | $5.00 | $8,000,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Sophiris Bio (NASDAQ:SPHS)
Latest Headlines for Sophiris Bio (NASDAQ:SPHS)
| Source: |
|
| Date | Headline |
|---|
 | HC Wainwright Reaffirms "Buy" Rating for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - September 15 at 4:52 PM |
 | Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank
finance.yahoo.com - September 14 at 10:28 AM |
| Sophiris Bio, Inc. (SPHS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 9 at 2:50 PM |
 | Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - PR Newswire (press release)
www.prnewswire.com - August 19 at 7:44 AM |
| Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - August 18 at 7:27 AM |
| Q3 2017 Earnings Forecast for Sophiris Bio, Inc. Issued By Zacks Investment Research (SPHS)
www.americanbankingnews.com - August 18 at 6:24 AM |
| Sophiris Bio, Inc. (SPHS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM |
| HC Wainwright Reiterates "$6.00" Price Target for Sophiris Bio, Inc. (SPHS)
www.americanbankingnews.com - August 13 at 3:32 PM |
| Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - August 11 at 8:45 AM |
| Brokerages Anticipate Sophiris Bio, Inc. (SPHS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - July 25 at 9:03 AM |
| Contrasting Parnell Pharmaceuticals Holdings (PARN) and Sophiris Bio (SPHS)
www.americanbankingnews.com - July 23 at 7:25 AM |
| Sophiris Bio, Inc. (NASDAQ:SPHS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM |
| Mylan N.V. (MYL) and Sophiris Bio (SPHS) Head-To-Head Review
www.americanbankingnews.com - July 16 at 6:20 PM |
| Comparing Sophiris Bio (SPHS) & Mylan N.V. (MYL)
www.americanbankingnews.com - July 11 at 8:26 PM |
| Financial Analysis: Parnell Pharmaceuticals Holdings (PARN) & Sophiris Bio (NASDAQ:SPHS)
www.americanbankingnews.com - July 8 at 2:18 PM |
| Sophiris Bio (SPHS) vs. Parnell Pharmaceuticals Holdings (PARN) Head to Head Analysis
www.americanbankingnews.com - June 29 at 4:07 PM |
| Analysts Expect Sophiris Bio, Inc. (SPHS) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - June 29 at 12:16 AM |
| Sophiris Bio, Inc. (SPHS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 8:56 PM |
| Sophiris Bio Added to Russell Microcap Index
finance.yahoo.com - June 24 at 6:55 AM |
| Sophiris Bio, Inc. (SPHS) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - June 13 at 3:28 PM |
| Sophiris Bio, Inc. (SPHS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - June 11 at 10:52 PM |
| Maxim Group Analysts Give Sophiris Bio Inc (SPHS) a $6.00 Price Target
www.americanbankingnews.com - June 11 at 8:30 AM |
 | Sophiris Bio (SPHS) Doses First Patient in Phase 2b Study of Topsalysin to Treat Prostate Cancer - StreetInsider.com
www.streetinsider.com - June 10 at 1:13 AM |
 | Sophiris Bio Begins Dosing Patients in Phase 2b Study of Topsalysin to Treat Prostate Cancer
www.nasdaq.com - June 9 at 12:06 AM |
| Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer
finance.yahoo.com - June 8 at 8:06 AM |
| Analysts Expect Sophiris Bio Inc (SPHS) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - June 2 at 10:26 PM |
| Sophiris Bio Inc (SPHS) Receives Buy Rating from Rodman & Renshaw
www.americanbankingnews.com - June 1 at 7:28 PM |
| Sophiris Bio Inc (SPHS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 6:34 PM |
| Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer
finance.yahoo.com - May 23 at 7:20 PM |
| FY2017 EPS Estimates for Sophiris Bio Inc Decreased by Zacks Investment Research (SPHS)
www.americanbankingnews.com - May 22 at 7:18 AM |
| SPHS: Dosing of Patients in Phase 2b Trial of Topsalysin in Prostate Cancer to Initiate Soon
finance.yahoo.com - May 19 at 10:05 AM |
| Sophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at AUA
www.streetinsider.com - May 16 at 7:54 PM |
| Sophiris Bio Inc (SPHS) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - May 16 at 10:54 AM |
| BUZZ-U.S. STOCKS ON THE MOVE-Snap, Home Depot, Pfizer, Akebia - Nasdaq
www.nasdaq.com - May 16 at 9:05 AM |
| Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights
finance.yahoo.com - May 15 at 7:09 PM |
| Sophiris Bio (SPHS) Presents Topsalysin Data from Phase 2a Proof ... - StreetInsider.com
www.streetinsider.com - May 15 at 9:12 AM |
| Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting
finance.yahoo.com - May 15 at 9:12 AM |
| Sophiris Bio Inc (SPHS) Short Interest Update
www.americanbankingnews.com - May 12 at 3:40 PM |
| -$0.09 Earnings Per Share Expected for Sophiris Bio Inc (SPHS) This Quarter
www.americanbankingnews.com - May 9 at 12:28 PM |
| Sophiris Bio Inc (SPHS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 5 at 11:38 AM |
| Sophiris Bio (SPHS) Earning Positive Press Coverage, Study Finds
www.americanbankingnews.com - May 4 at 12:12 PM |
| Sophiris Bio (SPHS) Getting Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 25 at 11:44 AM |
| Brokerages Expect Sophiris Bio Inc (SPHS) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - April 18 at 4:31 PM |
| Sophiris Bio (SPHS) Getting Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 18 at 3:45 PM |
| Sophiris Bio (SPHS) Earns Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 13 at 5:03 PM |
| Sophiris Bio Inc (SPHS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 10 at 11:44 AM |
| Sophiris Bio Inc (SPHS) Earns Overweight Rating from Piper Jaffray Companies
www.americanbankingnews.com - April 6 at 9:46 AM |
| Sophiris Bio Inc (SPHS) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 3 at 12:25 PM |
| Sophiris Bio Inc Forecasted to Post Q1 2017 Earnings of ($0.08) Per Share (SPHS)
www.americanbankingnews.com - March 31 at 10:32 AM |
| SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway
finance.yahoo.com - March 30 at 12:13 AM |
Sophiris Bio (SPHS) Chart for Thursday, September, 21, 2017
